{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:27:08Z","timestamp":1777595228768,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jns.2023.120619","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T12:42:03Z","timestamp":1679488923000},"page":"120619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST"],"prefix":"10.1016","volume":"448","author":[{"given":"Takayasu","family":"Mishima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Wei","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemoto","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Shimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jns.2023.120619_bb0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jns.2023.120619_bb0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann. Neurol."},{"issue":"Pt 10","key":"10.1016\/j.jns.2023.120619_bb0015","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.jns.2023.120619_bb0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2023.120619_bb0025","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1212\/WNL.0000000000006737","article-title":"Age and time course of long-term motor and nonmotor complications in Parkinson disease","volume":"92","author":"Prange","year":"2019","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2023.120619_bb0030","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10072-019-03920-5","article-title":"Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease: causes of discontinuation and subsequent treatment strategies","volume":"40","author":"Olivola","year":"2019","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2023.120619_bb0035","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2023.120619_bb0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JPD-2012-120103","article-title":"Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life","volume":"2","author":"Manson","year":"2012","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.jns.2023.120619_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-0037-1602423","article-title":"Motor complications of dopaminergic medications in Parkinson\u2019s disease","volume":"37","author":"Freitas","year":"2017","journal-title":"Semin. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2023.120619_bb0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/NRL.0b013e3181be6d15","article-title":"The impact of levodopa on quality of life in patients with Parkinson disease","volume":"16","author":"Sethi","year":"2010","journal-title":"Neurologist"},{"issue":"12","key":"10.1016\/j.jns.2023.120619_bb0055","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","article-title":"Effects of dyskinesias in Parkinson\u2019s disease on quality of life and health-related costs: a prospective European study","volume":"12","author":"P\u00e9chevis","year":"2005","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2023.120619_bb0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson\u2019s disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.jns.2023.120619_bb0065","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00415-012-6557-8","article-title":"The progression of non-motor symptoms in Parkinson\u2019s disease and their contribution to motor disability and quality of life","volume":"259","author":"Antonini","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2023.120619_bb0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jns.2016.12.060","article-title":"Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson\u2019s disease","volume":"373","author":"Balestrino","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2023.120619_bb0075","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/ene.12950","article-title":"The impact of non-motor symptoms on the quality of life of Parkinson\u2019s disease patients: a longitudinal study","volume":"23","author":"Prakash","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2023.120619_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41531-018-0069-x","article-title":"Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort","volume":"4","author":"Eusebi","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"issue":"8","key":"10.1016\/j.jns.2023.120619_bb0085","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/mds.27783","article-title":"Predictors of motor complications in early Parkinson\u2019s disease: a prospective cohort study","volume":"34","author":"Kelly","year":"2019","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.jns.2023.120619_bb0090","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease","volume":"28","author":"Warren Olanow","year":"2013","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.jns.2023.120619_bb0095","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.clineuro.2006.02.002","article-title":"A hospital-based study: risk factors in development of motor complications in 555 Parkinson\u2019s patients on levodopa therapy","volume":"108","author":"Benbir","year":"2006","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2023.120619_bb0100","first-page":"8692509","article-title":"Analysis of motor complication and relative factors in a cohort of Chinese patients with Parkinson's disease","volume":"2020","author":"Sun","year":"2020","journal-title":"Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.jns.2023.120619_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/cjn.2015.328","article-title":"Parkinson disease: the relationship between non-motor symptoms and motor phenotype","volume":"43","author":"Ba","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.jns.2023.120619_bb0110","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/mds.27181","article-title":"Impulse control disorders in advanced Parkinson\u2019s disease with dyskinesia: the ALTHEA study","volume":"32","author":"Biundo","year":"2017","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jns.2023.120619_bb0115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/ene.12583","article-title":"Action tremor in Parkinson\u2019s disease: frequency and relationship to motor and non-motor signs","volume":"22","author":"Gigante","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2023.120619_bb0120","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1007\/s00415-018-8913-9","article-title":"Correlation among olfactory function, motors\u2019 symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson\u2019s disease","volume":"265","author":"Masala","year":"2018","journal-title":"J. Neurol."},{"issue":"24","key":"10.1016\/j.jns.2023.120619_bb0125","first-page":"5745","article-title":"The non-motor symptoms of Parkinson\u2019s disease of different motor types in early stage","volume":"21","author":"Zhong","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2023.120619_bb0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","article-title":"Risk factors for non-motor symptoms in Parkinson\u2019s disease","volume":"17","author":"Marinus","year":"2018","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2023.120619_bb0135","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/ene.14221","article-title":"Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson\u2019s disease","volume":"27","author":"Santos-Garc\u00eda","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"13","key":"10.1016\/j.jns.2023.120619_bb0140","doi-asserted-by":"crossref","first-page":"e1468","DOI":"10.1212\/WNL.0000000000007189","article-title":"Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD","volume":"92","author":"Yoo","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2023.120619_bb0145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2017.02.024","article-title":"Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson\u2019s disease patients from 35 medical centers","volume":"38","author":"Maeda","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2023.120619_bb0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mdc3.12939","article-title":"Real-world nonmotor changes in patients with Parkinson's disease and motor fluctuations: J-FIRST","volume":"7","author":"Watanabe","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"2","key":"10.1016\/j.jns.2023.120619_bb0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-019-0294-x","article-title":"Sex differences in movement disorders","volume":"16","author":"Meoni","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2023.120619_bb0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mds.28312","article-title":"Differences in the presentation and progression of Parkinson\u2019s disease by sex","volume":"36","author":"Iwaki","year":"2021","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.jns.2023.120619_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237472","article-title":"Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease","volume":"15","author":"Hong","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jns.2023.120619_bb0170","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00415-016-8384-9","article-title":"The relevance of gender in Parkinson\u2019s disease: a review","volume":"264","author":"Picillo","year":"2017","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2023.120619_bb0175","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/14737175.6.3.407","article-title":"Gender disparities in Parkinson\u2019s disease","volume":"6","author":"Shulman","year":"2006","journal-title":"Expert. Rev. Neurother."},{"issue":"1","key":"10.1016\/j.jns.2023.120619_bb0180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00702-016-1671-x","article-title":"Long-term treatment of Parkinson\u2019s disease with levodopa and other adjunctive drugs","volume":"125","author":"Mizuno","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"6","key":"10.1016\/j.jns.2023.120619_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099021","article-title":"Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010","volume":"9","author":"Nakaoka","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2023.120619_bb0190","first-page":"2735361","article-title":"Motor\/nonmotor symptoms and progression in patients with Parkinson's disease: prevalence and risks in a longitudinal study","volume":"2020","author":"Yoritaka","year":"2020","journal-title":"Parkinsons Dis."},{"issue":"8","key":"10.1016\/j.jns.2023.120619_bb0195","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.parkreldis.2013.04.001","article-title":"Motor and non-motor symptoms of 1453 patients with Parkinson\u2019s disease: prevalence and risks","volume":"19","author":"Yoritaka","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10","key":"10.1016\/j.jns.2023.120619_bb0200","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jnnp.2011.240366","article-title":"The natural history of treated Parkinson\u2019s disease in an incident, community based cohort","volume":"82","author":"Evans","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2023.120619_bb0205","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00702-011-0698-2","article-title":"Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation","volume":"118","author":"Iravani","year":"2011","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.jns.2023.120619_bb0210","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/JEP.S265282","article-title":"Pathophysiological mechanisms and experimental pharmacotherapy for L-dopa-induced dyskinesia","volume":"13","author":"Fabbrini","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.jns.2023.120619_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/PROM.S29443","article-title":"Patient perspectives on Parkinson\u2019s disease therapy in Japan and the United States: results of two patient surveys","volume":"3","author":"Hattori","year":"2012","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.jns.2023.120619_bb0220","first-page":"9237181","article-title":"Patterns and determinants of prescribing for Parkinson's disease: a systematic literature review","volume":"2019","author":"Orayj","year":"2019","journal-title":"Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.jns.2023.120619_bb0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1358\/dot.2010.46.4.1490077","article-title":"Zonisamide: a new drug for Parkinson\u2019s disease","volume":"46","author":"Murata","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jns.2023.120619_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.574652","article-title":"Zonisamide for the treatment of Parkinson disease: a current update","volume":"14","author":"Li","year":"2020","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2023.120619_bb0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"The Japan Zonisamide on PD Study Group, Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2023.120619_bb0240","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.26286","article-title":"Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study","volume":"30","author":"Murata","year":"2015","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2023.120619_bb0245","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/neurolint12030017","article-title":"Istradefylline to treat patients with Parkinson\u2019s disease experiencing \u201coff\u201d episodes: a comprehensive review","volume":"12","author":"Berger","year":"2020","journal-title":"Neurol. Int."},{"issue":"3","key":"10.1016\/j.jns.2023.120619_bb0250","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14737175.2021.1880896","article-title":"Istradefylline - a first generation adenosine A(2A) antagonist for the treatment of Parkinson\u2019s disease","volume":"21","author":"Jenner","year":"2021","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jns.2023.120619_bb0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.parkreldis.2021.09.015","article-title":"Influence of istradefylline on non-motor symptoms of Parkinson\u2019s disease: a subanalysis of a 1-year observational study in Japan (J-FIRST)","volume":"91","author":"Shimo","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2023.120619_bb0260","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pbj.2016.08.001","article-title":"Parkinson\u2019s disease and development of levodopa induced motor complications: influence of baseline features and first medical approach","volume":"1","author":"Rua Rafael","year":"2016","journal-title":"Porto Biomed. J."},{"issue":"1","key":"10.1016\/j.jns.2023.120619_bb0265","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mdc3.13117","article-title":"Apathy and anxiety in de novo Parkinson's disease predict the severity of motor complications","volume":"8","author":"Hinkle","year":"2021","journal-title":"Mov. Disord. Clin. Pract."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:01:58Z","timestamp":1758384118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X23000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":53,"alternative-id":["S0022510X23000795"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2023.120619","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2023.120619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120619"}}